

# Cooper Companies, Inc. (COO)

Nasdaq; healthcare; SIC 3851, Ophthalmic Goods; CIK 0000711404

|                                                  |                                                                                                                                                                                                                            |
|--------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cooper Companies, Inc.</b><br>COO; healthcare |                                                                                                                                                                                                                            |
| <b>Grade</b>                                     | <div><div>C</div><div><div></div><div></div><div></div><div></div><div></div></div><div>A B C D E</div><div>middle fifth of 371 graded peers<br/>percentile 56.8; sampling error 2.5 points; lower is stronger</div></div> |
| <b>Rank</b>                                      | 211 of 371                                                                                                                                                                                                                 |
| <b>Profitability</b>                             | C <div><div></div><div></div><div></div><div></div><div></div></div> percentile 51.4                                                                                                                                       |
| <b>Solvency</b>                                  | C <div><div></div><div></div><div></div><div></div><div></div></div> percentile 49.6                                                                                                                                       |
| <b>Growth and financing</b>                      | C <div><div></div><div></div><div></div><div></div><div></div></div> percentile 49.2                                                                                                                                       |
| <b>Reliability</b>                               | 0.94 AUC<br>filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025                                                                                                                            |
| <b>Peer failure rate</b>                         | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025                                                                                                                                                      |
| <b>Size band</b>                                 | over \$2.67B assets<br>total assets \$12.4B                                                                                                                                                                                |
| <b>Standard universe</b>                         | inside<br>revenue above \$1M and assets above \$10M                                                                                                                                                                        |
| <b>Warnings</b>                                  | none active<br>not computable: distress                                                                                                                                                                                    |
| <b>Inputs computable</b>                         | 12 of 14                                                                                                                                                                                                                   |
| <b>Graded from</b>                               | filings received through Dec 5, 2025<br>308 days before the rescans; latest periodic filing 10-Q received Sep 9, 2026                                                                                                      |
| <b>Last close</b>                                | \$54.29<br>2026-10-08; market equity \$10.3B                                                                                                                                                                               |
| <b>Price used in grade</b>                       | None                                                                                                                                                                                                                       |



**C, the tortoise**  
middle fifth of its sector; letters are fifths of the 371 graded peers

**Share price, twelve months to the rescans**  
*split-adjusted close; the letter is fixed at the rescans that set it*



Rescans on file: B from Dec 21, 2023, C from Dec 21, 2024, C/D from Apr 21, 2025

**Letter at every rescan**

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



## Business, in the company's words

opening of Item 1 of the 10-K received Dec 5, 2025

The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. Headquartered in San Ramon, California, Cooper sells products in over 130 countries and positively impacts over fifty million lives each year. Cooper operates through two business segments, CooperVision and CooperSurgical. Our two business segments elevate standards of care with products and services in the fields of vision, fertility and

women's health. For financial information relating to these business segments, refer to Note 12. Business Segment Information in Item 8.


## The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

| Input                                               | Percentile, 0 to 100 | Value          | Peer median | Percentile | Peers | Period end                                                                                 |
|-----------------------------------------------------|----------------------|----------------|-------------|------------|-------|--------------------------------------------------------------------------------------------|
| <b>Profitability, sleeve percentile 51.4</b>        |                      |                |             |            |       |                                                                                            |
| Gross profitability                                 |                      | 21.6%          | 32.2%       | 62.3       | 372   | 2025-10-31                                                                                 |
| Return on invested capital                          |                      | 4.3%           | 9.3%        | 63.0       | 74    | 2025-10-31                                                                                 |
| Accruals ratio                                      |                      | (3.4%)         | (6.6%)      | 69.5       | 811   | 2025-10-31                                                                                 |
| Gross margin stability, five years                  |                      | 0.8 pts        | 2.8 pts     | 10.7       | 243   | 2025-10-31                                                                                 |
| <b>Solvency, sleeve percentile 49.6</b>             |                      |                |             |            |       |                                                                                            |
| Twelve-month failure probability                    |                      | not computable | 0.07%       |            |       | latest liabilities, cash plus short-term investments, book equity, and shares are required |
| Altman Z double-prime                               |                      | 4.99           | (0.31)      | 18.7       | 756   | 2025-10-31                                                                                 |
| Net debt to EBITDA                                  |                      | 2.21x          | 1.82x       | 56.8       | 75    | 2025-10-31                                                                                 |
| Interest coverage                                   |                      | not computable | (4.51x)     |            |       | latest aligned inputs end 2023-10-31; latest annual assets end 2025-10-31                  |
| Current ratio                                       |                      | 1.89x          | 2.96x       | 73.5       | 839   | 2025-10-31                                                                                 |
| <b>Growth and financing, sleeve percentile 49.2</b> |                      |                |             |            |       |                                                                                            |
| Revenue growth, three-year compound                 |                      | 7.3%           | 10.0%       | 55.3       | 415   | 2025-10-31                                                                                 |
| Free cash flow growth, three-year compound          |                      | (1.3%)         | 10.9%       | 74.7       | 96    | 2025-10-31                                                                                 |
| Reinvestment rate                                   |                      | 11.0%          | 37.1%       | 63.1       | 104   | 2025-10-31                                                                                 |
| Asset growth, three years                           |                      | 2.6%           | 2.1%        | 45.4       | 704   | 2025-10-31                                                                                 |
| Net share issuance, one year                        |                      | (1.8%)         | 2.5%        | 7.3        | 634   | 2025-12-01                                                                                 |

## Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

| Rank | Company                        | Percentile | Letter | Warnings      |
|------|--------------------------------|------------|--------|---------------|
| 206  | Regenxbio Inc. (RGNX)          | 55.4       | C      | short runway  |
| 207  | ELI Lilly & Co. (LLY)          | 55.7       | C      |               |
| 208  | Cabaletta Bio, Inc. (CABA)     | 55.9       | C      | dilution      |
| 209  | AdaptHealth Corp. (AHCO)       | 56.2       | C      |               |
| 210  | Inogen Inc. (INGN)             | 56.5       | C      | fortress      |
|      |                                |            |        | balance sheet |
| 211  | Cooper Companies, Inc. (COO) < | 56.8       | C      |               |

|     |                                     |      |                       |
|-----|-------------------------------------|------|-----------------------|
| 212 | Aquestive Therapeutics, Inc. (AQST) | 57.0 | C                     |
| 213 | Tango Therapeutics, Inc. (TNGX)     | 57.3 | C dilution            |
| 214 | Cryo Cell International Inc. (CCEL) | 57.6 | C/D                   |
| 215 | electroCore, Inc. (ECOR)            | 57.8 | C/D                   |
| 216 | Rocket Pharmaceuticals, Inc. (RCKT) | 58.1 | C/D degenerate inputs |

### What the price implies

at the 2026-10-08 close; none enters the grade

| Measure                                                 | Value   | Peer median | Percentile |
|---------------------------------------------------------|---------|-------------|------------|
| Twelve-month price change, skipping the latest month    | 2.2%    | 8.0%        | 47         |
| Distance from 52-week high                              | (35.6%) | (31.4%)     | 43         |
| EBIT to enterprise value                                | 5.6%    | (1.5%)      | 81         |
| Free cash flow yield                                    | 4.2%    | (1.0%)      | 77         |
| Book value to price                                     | 0.81    | 0.28        | 80         |
| Sales to price                                          | 0.40    | 0.31        | 58         |
| Composite equity issuance, five years                   | (3.3%)  | 20.3%       | 22         |
| Relative strength against the sector, log excess return | (0.19)  | (0.14)      | 47         |

### Diagnostics

not in the grade

| Measure                                                | Value                          |
|--------------------------------------------------------|--------------------------------|
| <b>Piotroski F-score 5 of 9, period end 2025-10-31</b> |                                |
| Return on assets above zero                            | pass                           |
| Operating cash flow above zero                         | pass                           |
| Return on assets improved                              | fail                           |
| Operating cash flow exceeds net income                 | pass                           |
| Long-term leverage fell                                | pass                           |
| Current ratio improved                                 | fail                           |
| No new shares issued                                   | pass                           |
| Gross margin improved                                  | fail                           |
| Asset turnover improved                                | fail                           |
| <b>Cash, filings, liquidity</b>                        |                                |
| Cash and equivalents                                   | \$154.7M                       |
| Operating cash flow, four quarters                     | \$1.0B                         |
| Months of runway                                       | not finite                     |
| Days since last periodic filing                        | 30 (10-Q received Sep 9, 2026) |
| Median daily dollar volume, 63 sessions                | \$148.7M                       |

### Sources

each row links to the filing index on sec.gov

| #  | Concept             | XBRL tag                                                                                     | Value    | Period end | Received   | Form | Accession            |
|----|---------------------|----------------------------------------------------------------------------------------------|----------|------------|------------|------|----------------------|
| 1  | gross profit        | us-gaap:GrossProfit                                                                          | \$2.7B   | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 2  | assets              | us-gaap:Assets                                                                               | \$12.4B  | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 3  | operating income    | us-gaap:OperatingIncomeLoss                                                                  | \$682.9M | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 4  | pretax income       | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems | \$566.5M | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 5  | income tax          | us-gaap:IncomeTaxExpenseBenefit                                                              | \$191.6M | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 6  | total debt          | us-gaap:LongTermDebtAndCapitalLeaseObligations                                               | \$2.5B   | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 7  | book equity         | us-gaap:StockholdersEquity                                                                   | \$8.2B   | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 8  | cash                | us-gaap:CashAndCashEquivalentsAtCarryingValue                                                | \$110.6M | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 9  | total debt          | us-gaap:LongTermDebtAndCapitalLeaseObligations                                               | \$2.6B   | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 10 | book equity         | us-gaap:StockholdersEquity                                                                   | \$8.1B   | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 11 | cash                | us-gaap:CashAndCashEquivalentsAtCarryingValue                                                | \$107.6M | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 12 | net income          | us-gaap:NetIncomeLoss                                                                        | \$374.9M | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities                                           | \$796.1M | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 14 | assets              | us-gaap:Assets                                                                               | \$12.3B  | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 15 | revenue             | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax                                  | \$4.1B   | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 16 | gross profit        | us-gaap:GrossProfit                                                                          | \$2.6B   | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |

|    |                           |                                                             |             |            |            |      |                      |
|----|---------------------------|-------------------------------------------------------------|-------------|------------|------------|------|----------------------|
| 17 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$3.9B      | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 18 | gross profit              | us-gaap:GrossProfit                                         | \$2.4B      | 2023-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 19 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$3.6B      | 2023-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 20 | gross profit              | us-gaap:GrossProfit                                         | \$2.1B      | 2022-10-31 | 2024-12-06 | 10-K | 0000711404-24-000074 |
| 21 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$3.3B      | 2022-10-31 | 2024-12-06 | 10-K | 0000711404-24-000074 |
| 22 | gross profit              | us-gaap:GrossProfit                                         | \$2.0B      | 2021-10-31 | 2023-12-08 | 10-K | 0000711404-23-000072 |
| 23 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | \$2.9B      | 2021-10-31 | 2023-12-08 | 10-K | 0000711404-23-000072 |
| 24 | current assets            | us-gaap:AssetsCurrent                                       | \$2.1B      | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 25 | current liabilities       | us-gaap:LiabilitiesCurrent                                  | \$1.1B      | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 26 | retained earnings         | us-gaap:RetainedEarningsAccumulatedDeficit                  | \$7.6B      | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 27 | liabilities               | us-gaap:Liabilities                                         | \$4.2B      | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 28 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization                | \$377.4M    | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 29 | operating income          | us-gaap:OperatingIncomeLoss                                 | \$533.1M    | 2023-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 30 | interest expense          | us-gaap:InterestExpense                                     | \$105.3M    | 2023-10-31 | 2023-12-08 | 10-K | 0000711404-23-000072 |
| 31 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$362.4M    | 2025-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 32 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities          | \$709.3M    | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 33 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$421.2M    | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 34 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities          | \$607.5M    | 2023-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 35 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$392.5M    | 2023-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 36 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivities          | \$692.4M    | 2022-10-31 | 2024-12-06 | 10-K | 0000711404-24-000074 |
| 37 | capital expenditure       | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment          | \$242.0M    | 2022-10-31 | 2024-12-06 | 10-K | 0000711404-24-000074 |
| 38 | current assets            | us-gaap:AssetsCurrent                                       | \$2.0B      | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 39 | current liabilities       | us-gaap:LiabilitiesCurrent                                  | \$1.0B      | 2024-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 40 | assets                    | us-gaap:Assets                                              | \$11.7B     | 2023-10-31 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 41 | assets                    | us-gaap:Assets                                              | \$11.5B     | 2022-10-31 | 2024-12-06 | 10-K | 0000711404-24-000074 |
| 42 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                      | 195,978,026 | 2025-12-01 | 2025-12-05 | 10-K | 0001628280-25-055615 |
| 43 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                      | 199,582,626 | 2024-11-29 | 2024-12-06 | 10-K | 0000711404-24-000074 |